Obesity in children and adolescents — compounds assessed

§4Compounds assessed

Compounds the Institute assesses in this indication, with the class of each and its overall certainty. A compound appears here whether or not the evidence supports its use, because recording that a compound has been studied and found wanting is as much part of the assessment as recording that one has not.

• Liraglutide in adolescent obesity

  GLP-1 receptor agonist (acylated, once-daily)1 contributing trialfull monograph

  BMI z-score reduction of 0.22 versus 0.01 with placebo at 56 weeks — Smaller effect than semaglutide in an equivalent population.

  Moderate
• Semaglutide in adolescent obesity

  GLP-1 receptor agonist (acylated, long-acting)1 contributing trialfull monograph

  −16.1 % BMI at 68 weeks versus +0.6 % with placebo — Downgraded for imprecision in subgroups and absence of growth and bone-accrual follow-up.

  Moderate

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DCW, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JPH. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine 2015;373(1):11–22. doi:10.1056/NEJMoa1411892 · PMID 26132939

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.